IQ-AI Ltd (LSE:IQAI, OTCQB:IQAIF) said its subsidiary, Imaging Biometrics, had its most successful year in 2021.
The subsidiary, which develops and provides visualisation and analytical solutions that enable clinicians to better diagnose and treat disease, sent a letter to shareholders trumpeting its achievements in the year just ended.
The company told shareholders this year will see it continue its development efforts on other key initiatives including IB Trax for the tracking of metastatic lesions. Brain metastases are 10 times more prevalent than primary brain tumours and clinicians lack a robust and streamlined tracking and monitoring platform, Imaging Biometrics said.
“IB Delta T1 maps (patent pending) will be used to help delineate lesions and since IB Delta T1 maps are quantitative, volumetric longitudinal assessment can be done for both individual lesion and whole-brain analyses,” the company added.
Imaging Biometrics has completed its marketing plans for 2022 and is adequately resourced to execute them.
“We intend to participate at several trade shows directly and many more through our channel partners and the conferences they attend. Maintaining and building upon the momentum gained during 2021 with sales of IB-ce will be critical to this year's results, and we are especially optimistic that 2022 will be a breakthrough year for our channel partners. Our regulatory strategy, including the preparation and submission of IB Zero G's 510(k) application to the FDA [US Food and Drug Administration], warrants adequate and appropriate resources during Q1 [first quarter],” the company added.
Shares in IQ-AI were up 2.2% at 5.875p in early deals.